Completing my PhD studies on food allergens at James Cook University, under Professor Andreas Lopata, I developed skills and experience in protein chemistry and protein-based assays. I then joined SVI’s DNA Repair and Recombination laboratory, to develop and perform a large drug screen searching for a targeted new treatment for ‘BRCA’ breast and ovarian cancers.
My goal is to target the Fanconi anaemia pathway, a cellular DNA repair mechanism vital to the survival of breast and ovarian cancer cells. I have now screened more than 55,000 potential new drugs and am currently characterising just a handful of these for their anti-cancer properties.
Another research interest developed from this work is the rare genetic disorder, Fanconi anaemia, which leads to high cancer predisposition, bone marrow failure, infertility and developmental defects. Through building understanding of the Fanconi anaemia pathway proteins and their interactions on a molecular level, I aim to improve health outcomes for people with this condition.
Key achievements
2022 SVI Postdoctoral Society leader; Harold Mitchell Foundation Travel Grant
2021 SVI Rising Star Award
2020 TIA Pipeline Accelerator Fund Grant; SVI, Most Outstanding Seminar from a Postdoctoral Researcher
2019 Best Flash Talk Presentation, VCCC Postdoctoral Symposium; The CASS Foundation Travel Scholarship
2018 Best poster, VCCC Postdoctoral Symposium
DNA Repair & Recombination
Our vision is to translate basic knowledge of DNA repair pathways to treatments for cancer, bone marrow failure syndromes, and infertility.
Lab head: Associate Professor Wayne CrismaniSelected publications
Sharp, M. F., Bythell-Douglas, R., Deans, A. J. & Crismani, W. The Fanconi anemia ubiquitin E3 ligase complex as an anti-cancer target. Mol. Cell 81, 2278–2289 (2021).
Sharp, M. F., Taki, A. C., Ruethers, T., Stephen, J. N., Daly, N. L., Lopata, A. L., et al. IgE and IgG4 epitopes revealed on the major fish allergen Lat c 1. Mol. Immunol. 131, 155–163 (2021).
Tan, W., van Twest, S., Leis, A., Bythell-Douglas, R., Murphy, V. J., Sharp, M., et al. Monoubiquitination by the human Fanconi Anemia core complex clamps FANCI:FANCD2 on DNA in filamentous arrays. Elife 9, 1–20 (2020).
Sharp, M. F., Murphy, V. J., Twest, S. Van, Tan, W., Lui, J., Simpson, K. J., et al. Methodology for the identification of small molecule inhibitors of the Fanconi Anaemia ubiquitin E3 ligase complex. Sci. Rep. 10, 1–11 (2020).
Tan, W., Murphy, V. J., Charron, A., Van Twest, S., Sharp, M., Constantinou, A., et al. Preparation and purification of monoubiquitinated proteins using Avi-tagged ubiquitin. PLoS One 15, 1–16 (2020).
Sharp, M. F. & Lopata, A. L. Fish allergy: In review. Clin. Rev. Allergy Immunol. 46, 258–271 (2014).
ORCID profile: https://orcid.org/0000-0002-1019-3729
Related news
Dr Matthew Lacorcia
Senior Research Officer
Human Immunology
Vaccinating against type 1 diabetes
Type 1 diabetes develops when the immune system’s T cells gradually destroy the cells that make insulin. As a result, people with T1D require constant monitoring and frequent insulin injections to control their blood sugar levels.
Our long-term goal is to develop a type of vaccine that can stop the immune system destroying the insulin producing cells. However, to do this we need a test that can determine whose immune systems are starting to attack their insulin producing cells.
We also need a blood test that can tell doctors and scientist if new therapies, intended to stop this autoimmune response, are working without having to wait for years to see who develops type 1 diabetes.
The goal of this project is to develop, optimise and validate a new blood test than can measure the strength of the autoimmune response against the insulin producing cells.
Dr Matt Lacorcia is an immunologist. He did his PhD at the Technical University of Munich in Germany, and also holds a PhD in Creative Writing from the University of Melbourne.
Matt is using his skills to help develop a test that can measure the immune responses that indicate progression of type 1 diabetes using a small sample of blood from an affected individual.
Dr Martha Blank
Senior Research Officer
Bone Cell Biology
Paving the way for new treatments for osteoporosis
While we understand how bone is built, we do not understand how cells regulate bone material composition throughout life to maintain flexibility and toughness and therefore, bone strength.
Weak bones are more prone to break than strong bones which can lead to increasing complications as we age.
While we understand how bone is built, we do not understand how cells regulate bone material composition throughout life to maintain flexibility and toughness and therefore, bone strength.
Bone mass and bone material quality both contribute to bone health but current treatments to improve bone strength are focused only on bone mass: they aim to increase mass by stimulating bone formation or by maintaining bone mass through the inhibition of bone loss. This project seeks to identify novel pathways which could improve bone quality in order to keep bone material strong and healthy.
Our ultimate goal is to understand how bone strength can be improved without needing to form new bone which may also be useful for other bone diseases.
Dr Martha Blank’s research focuses on understanding the factors that help maintain bone strength.
Martha carried out her undergraduate studies at the University of Applied Sciences in Vienna, Austria, before completing her PhD at SVI in 2022. She is expert in techniques that are used to analyse the composition of bone and is applying these to better understand how bone cells regulate collagen and mineral in bone tissue and how this influences bone strength.
Dr Chris Chiu
Postdoctoral Researcher
Islet Biology
Testing a new treatment for type 1 diabetes
Type 1 diabetes is an autoimmune condition in which the insulin-producing cells are targeted and destroyed by cells of the immune system in the pancreas. Since insulin was discovered 100 years ago, there have been no real changes to treatment of type 1 diabetes.
Chris’ lab is investigating how a drug called baricitinib works to slow and even stop the progression of type 1 diabetes by protecting the insulin protecting cells from being attacked by the body’s immune system.
“We know that baricitinib can slow the progression of type 1 diabetes but what we are now looking at is how it does that. Understanding this can help pave the way for eventually finding a cure for type 1 diabetes.”
Dr Chris Chiu is a bioinformatician with both wet- and dry lab expertise.
He joined SVI in 2023, following a postdoc at the Peter Doherty Institute and completing his PhD at WEHI. He is applying his skills to understand the effect of the drug baricitinib in people with recently diagnosed type 1 diabetes who were enrolled in SVI’s BANDIT clinical trial.